Neurocrine Biosciences Highlights Key September Investor Events
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has a series of important presentations lined up for September that will engage investors and showcase the company's ongoing efforts in neuroscience. The events are designed to provide insights into their latest developments and future aspirations in the biopharmaceutical landscape.
Upcoming Investor Conferences
In this busy month, several key figures from Neurocrine Biosciences will take the stage to discuss the company’s evolving strategies and innovative treatments. Firstly, Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference. This presentation is scheduled for 1:00 p.m. ET on the first Wednesday in September.
Additionally, Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani are set to address the audience at the Morgan Stanley 23rd Annual Global Healthcare Conference. They will be presenting at 10:45 a.m. ET on the following Tuesday.
Highlighting Therapeutic Innovations
Following that, Gano and Keswani, along with Todd Tushla, will feature at the Baird 2025 Global Healthcare Conference. Their discussion will commence at 10:15 a.m. ET on the second Wednesday of September. These engagements are pivotal for raising awareness about Neurocrine’s advancements and initiatives aimed at treating neurological conditions.
Finally, the CEO alongside Todd Tushla will participate in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit at 12:40 p.m. ET on the third Wednesday of the month. This summit signifies Neurocrine’s commitment to exploring groundbreaking methods in neuropsychiatry.
Accessing Live Webcasts
Investors and interested parties can access live webcasts of these presentations on Neurocrine Biosciences' website under the Investors section. The website will also host replays of the webcasts, becoming available approximately one hour after each event concludes, and will remain archived for around one month. This is a fantastic opportunity for stakeholders to stay informed about the company's strategies and developments.
About Neurocrine Biosciences
Neurocrine Biosciences is dedicated to tackling the complexities associated with neurological disorders. The company focuses on creating, developing, and delivering innovative solutions for patients with significant unmet medical needs. Their extensive product portfolio includes FDA-approved treatments for several serious conditions, such as tardive dyskinesia and chorea related to Huntington's disease, as well as therapies for endocrinological and psychiatric disorders.
With a strong pipeline of promising treatments in various stages of development, Neurocrine leverages their experience in neuroscience to advance breakthroughs that impact patient lives. Their mission emphasizes relieving suffering and enhancing the quality of life for individuals experiencing these challenging health issues.
Commitment to Innovation
Neurocrine’s dedication to innovation is exemplified by its proactive approach in discovering therapies that address poorly managed health conditions. The company's robust research and development endeavors are aimed at delivering cutting-edge medicinal solutions that prioritize patient welfare.
Frequently Asked Questions
What is Neurocrine Biosciences?
Neurocrine Biosciences is a biopharmaceutical company specializing in neuroscience and committed to developing treatments for severe neurological and neuroendocrine disorders.
What conferences will Neurocrine attend in September?
Neurocrine will participate in several investor conferences, including the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and others.
Who are the key speakers from Neurocrine at these events?
Key speakers include CEO Kyle Gano, CFO Matt Abernethy, and Chief Medical Officer Sanjay Keswani, among others.
Where can I watch the live webcasts of the presentations?
Live webcasts can be accessed on Neurocrine Biosciences’ website under the Investors section.
How does Neurocrine contribute to neuroscience?
Neurocrine focuses on developing innovative treatments for neurological and related disorders, providing solutions that address significant unmet health needs.
